Alabama Brief Cognitive Screener (ABCs)

Slides:



Advertisements
Similar presentations
The Memory Assessment and Treatment Service (MATS)
Advertisements

APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Department of Neurology, Mayo Clinic Arizona
Management of Early Dementia Dr Eleanor Mullan Consultant Psychiatrist Mental Health Services for Older People South Lee, Cork Feb 2011.
Frontotemporal Dementia
Martha Stearn, MD Institute for Cognitive Health St John’s Medical Center Jackson, Wyoming.
©2011 MFMER | slide-1 Alzheimer Disease: Update Neill R. Graff-Radford, MBBCh, FRCP Professor of Neurology Mayo College of Medicine.
Alzheimer’s Disease By Juan Escobar Per: 4. Alzheimer’s Disease  A common form of dementia of unknown cause, usually beginning in late middle age, characterized.
Dementia and Aging Steven Huege, M.D Assistant Professor of Clinical Psychiatry Perelman School of Medicine at the University of Pennsylvania.
Dementia with Lewy Bodies
Mild Cognitive Impairment
Introduction to neuropsychiatric disorders
ACT on Alzheimer’s Disease Curriculum
ACT on Alzheimer’s Disease Curriculum Module VII: Disease Diagnosis.
How Alzheimer’s Disease Differs from Frontal Temporal Lobe Dementia (Pick’s Disease) Josepha A. Cheong, MD University of Florida Departments of Psychiatry.
Screening for Stroke and Cognitive Impairment Chapter 2: Background.
Alzheimer’s Disease and Biomarkers John H. Dougherty,Jr.M.D. Medical Director Cole Neuroscience Center.
Alzheimer’s Assessment Assessing the Cognitive-Linguistic effects of Alzheimer’s.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 22 Alzheimer’s Disease.
ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.
بسم الله الرحمن الرحیم. Dementia Dementia is a condition characterised by a progressive decline of mental abilities accompanied by changes in personality.
Clear organic causes, where primary symptom is a significant deficit in cognitive ability changes in the person’s personality and behavior (due to the.
Dementia Reed Radford. What is dementia?  Dementia is a serious loss of global cognitive ability, beyond what might be expected from normal aging. 
National Press Foundation R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington,
Mild Cognitive Impairment
How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
Introduction to neuropsychiatric disorders
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
Jack Twersky, MD Medical Director CLC Durham.  Memory impairment and at least one of the following  Aphasia  Apraxia  Agnosia  Executive function.
How to diagnose dementia? Dr. Sridhar Vaitheswaran 25 th October 2012.
HOW TO EXAMINE PATIENTS WITH DEMENTIA Serge Gauthier, MD, FRCPC McGill Centre for Studies in Aging Douglas Mental Health Research Institute.
The Dementias Dr Giles Richards Consultant Psychiatrist CFT.
MCI Conversion to Dementia: Clinic and Community-Based Studies
Neurocognitive Disorders: Delirium and Dementia Jamie Rusch.
A neurology primer. Hospital for Mentally Ill & Epileptics (Frankfurt )
Understanding Mild Cognitive Impairment. Objectives Understand the concept of MCI Identify risk factors for progression to dementia Review clinical trial.
Assessment and Diagnosis of Dementia Dr Alison Haddow.
CAROLINE HARADA, M.D. ASSOCIATE PROFESSOR OF MEDICINE UAB DIVISION OF GERONTOLOGY, GERIATRICS, AND PALLIATIVE CARE NOVEMBER 2013 Dementia.
Select Neurodegenerative Diseases. Alzheimer’s Disease.
Epidemiology of Alzheimer’s Disease
Dementia: Alzheimer’s Disease Cyril Evbuomwan Patient Group Meeting 1 st December 2015.
CSD 2230 HUMAN COMMUNICATION DISORDERS Topic 6 Language Disorders Adult Disorders Traumatic Brain Injury Dementia.
Cognitive Disorders Chapter 13 Nature of Cognitive Disorders: An Overview Perspectives on Cognitive Disorders Cognitive processes such as learning, memory,
The Alzheimer’s Disease Challenge: Take Your Knowledge Further ALZHEIMER’S DISEASE AND ITS MANAGEMENT: AN OVERVIEW.
Background. Vascular Cognitive Impairment Vascular Cognitive Impairment (VCI) includes the cognitive and behavioural disorders associated with cerebrovascular.
We Treat Alzheimers 20 years early? Can. Clinical neurologist-Reisa Sperling 1. Is a clinical neurologist, a neuroimaging researcher. 2.Is a leading force.
Mariano Musacchio 1 François Sellal 2 Frédéric Blanc 2 Jean-Marc Michel 2 Stephan Kremer 3 Jean-Louis Dietemann 3 1 Department of Neuroradiology - CHG.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
Structural and Functional Neuroimaging in the Diagnosis of Dementia John M. Ringman, M.D. Assistant Professor UCLA Department of Neurology.
Alzheimer's By Emily Toro Period 1.
Used to be called Dementia Neurocognitive Disorders.
Alzheimer’s Disease Update ALOMA February 2016 CME Conference Jennifer L. DeWolfe, DO Associate Professor of Neurology UAB Epilepsy Division Director,
The Public Health Impact Of Dementia And Alzheimer’s Disease: Challenges And Opportunities William W. Pendlebury, MD Emeritus Professor and Director,
The role of Nutrition in Geriatric Mental Health Chih-Chiang Chiu, M.D., Ph.D. Department of Psychiatry, Taipei City Psychiatric Center.
Memory and Aging Educational Presentation Presented by Tessa Lundquist, M.S. University of Massachusetts Amherst.
The Malfunctioning Mind: Degenerative Diseases of the Brain
The Malfunctioning Mind: Degenerative Diseases of the Brain
Volume 3, Issue 4, Pages (November 2017)
Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73
Dementia Jaqueline Raetz, M.D..
Aging & Alzheimer’s Disease
Abnormal Psychology Chapter 15 Neurocognitive Disorders Second Edition
Imaging AD Progression Amyloid Imaging Agents.
Cognitive Disorders and Aging
Reisa Sperling, Elizabeth Mormino, Keith Johnson  Neuron 
Chapter 93 Dementias and Related Disorders
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.
The Memory Assessment and Treatment Service (MATS)
Chapter 25 The Elderly.
Presentation transcript:

Alabama Brief Cognitive Screener (ABCs)

They’re impaired, what now? Screening labs for reversible causes: CBC Electrolytes, glucose, kidney function, liver function thyroid function vitamin B12 level Notably absent: syphilis screening unless they have a specific risk factor

Rule out cerebrovascular disease Neuroimaging “Structural Neuroimaging is appropriate to detect lesions that may result in cognitive impairment” * Rule out cerebrovascular disease detect segmental atrophy of neurodegenerative syndromes * “Practice Parameter: Diagnosis of Dementia” (Knopman et al, Neurology 2001:56:1143-53)

What is segmental atrophy? Duara et al, Neurology 2008:71:1986-92

Most Common Cause of Dementia

Aging and Preclinical Alzheimer’s disease Sperling et al. Alzheimer’s and Dementia, 2011;7:280-92.

Mild Cognitive Impairment due to Alzheimer’s disease Biomarker evidence of Aβ deposition (by PET or CSF) OR Evidence of Neuronal injury (MRI, CSF, or FDG-PET) NIA-AA criteria, 2011

Dementia due to Alzheimer’s disease- Insidious onset Clear-cut history of worsening of cognition Amnestic: most common, impaired learning and recall of recently learned information AND ≥ 1 other cognitive domain Nonamnestic: Language presentation: most prominent Visuospatial presentation: spatial cognition, including object agnosia, impaired face recognition, simultanagnosia, and alexia. Executive dysfunction: impaired reasoning, judgment, and problem solving. NIA-AA 2011 Criteria

DSM-V Criteria for Major Neurocognitive Disorder Due to Alzheimer’s Disease insidious onset & gradual progression ≥ 2 cognitive domains Probable- either: genetic mutation (fmh or test) 1) decline in memory & ≥ 1 other cognitive domain, AND 2) steady progression, AND 3) no evidence of mixed etiology Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association, 2013.